Investors
A MESSAGE FROM OUR CEO
”It is exciting to see the company’s pipeline continue to advance and the business case around AP1189 strengthening.”
-
February 1, 2023 RegulatoryPatrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
-
January 31, 2023 RegulatoryChange in number of shares and votes in SynAct Pharma
-
November 4, 2022 RegulatorySynAct Pharma publishes Q3 2022 interim report
-
August 5, 2022 RegulatorySynAct Pharma publishes Q2 2022 interim report